Ipca Laboratories stock reports stronger Q1 growth as guidance rises

Published on 10/07/2026 at 06:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ipca Laboratories stock was last at INR 1,942.70 on October 7, 2026, as Q1 FY27 revenue rose 20.8 percent to INR 2,788.1 crore. FY27 guidance spans 14-16 percent, with 18 analysts averaging INR 1,972.28.

Ipca Labs, INE571A01038, Illustration mit AI erstellt.

Ipca Laboratories stock was last at INR 1,942.70 on the NSE on October 7, 2026 at 10:18 a.m. IST, while the pharmaceutical company enters the second quarter with Q1 FY27 revenue up 20.8 percent to INR 2,788.1 crore. The results also pushed management's consolidated FY27 revenue-growth guidance to 14-16 percent from 12-13 percent, according to DSIJ in its August 17, 2026 report.

Q1 margins set the tone

Ipca's Q1 FY27 EBITDA reached INR 669.5 crore, a 60.8 percent year-over-year increase, and the EBITDA margin reached 24.0 percent. Profit after tax rose 72.3 percent to INR 401.9 crore, giving the earnings update a sharper margin profile than revenue growth alone would suggest.

The broader financial statement shows Q1 FY27 net income of INR 4,018.9 million and revenue of INR 27,881.0 million for the quarter ended June 30, 2026. The operating improvement matters because the latest growth has been supported by export formulations, APIs and the Unichem business, rather than by a single domestic product category.

Guidance moves above prior range

The upgraded FY27 revenue range of 14-16 percent compares with the earlier 12-13 percent range, while EBITDA margin guidance moved to 23 percent from 22 percent. Business Standard reported on September 16, 2026 that export revenue rose 34 percent in Q1 FY27, while operating margin expanded 450 basis points year over year to 22.9 percent.

The main counterweight is execution. DSIJ said on August 16, 2026 that Prabhudas Lilladher raised its target to INR 2,000 from INR 1,800, while also citing freight costs, institutional-business normalization and API capacity limits as constraints.

Analyst target stays near the quote

The analyst picture is constructive but measured. Investing.com lists 18 analysts with an average 12-month target of INR 1,972.28, a high of INR 2,190 and a low of INR 1,731. The average target lies 1.52 percent above the INR 1,942.70 price, making the guidance upgrade more important to the valuation debate than a large consensus gap.

Stock remains below yearly high

Ipca Laboratories stock was last at INR 1,942.70 on the NSE on October 7, 2026 at 10:18 a.m. IST. Its 52-week range was INR 1,251.60 to INR 2,038.00, while market capitalization stood at INR 492.9 billion and volume reached 18,603 shares.